Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 5/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 8/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17464320 | 0.84 | RET (0.38) | RETDUTPIM1PIM2CHEK1 | |
| SCHEMBL15894562 | 0.83 | FYN (0.45) | RETPIM1PIM2CHEK1CSNK2A2 | |
| SCHEMBL16154316 | 0.82 | DUT (0.38) | RETDUTPIM1PIM2CHEK1 | |
| SCHEMBL16088289 | 0.80 | STK17B (0.47) | PCSK9SUV39H2PIM1PIM2JAK2 | |
| SCHEMBL17077959 | 0.79 | RET (0.41) | RETPCSK9IRAK4PIM1PIM2 | |
| SCHEMBL15891374 | 0.78 | RET (0.40) | RETPCSK9IRAK4SUV39H2PIM1 | |
| SCHEMBL15894555 | 0.78 | SUV39H2 (0.51) | RETPCSK9IRAK4SUV39H2PIM1 | |
| SCHEMBL30103007 | 0.74 | PIM1 (0.40) | RETIRAK4PIM1PIM2KDR | |
| SCHEMBL15891391 | 0.73 | CA12 (0.45) | PCSK9IRAK4SUV39H2JAK2NTRK1 | |
| SCHEMBL15891328 | 0.72 | RET (0.41) | RETPCSK9IRAK4SUV39H2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096609-B2 | Macrocyclic LRRK2 kinase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2015-08-04 | — | — | US | disclosed |
| US-20140206683-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206683-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PINK1, PARK7 | RET 404/4885PCSK9 676/4885IRAK4 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.